CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Effective December 4, 2018, the Compensation Committee of Caladrius Biosciences, Inc. (the “Company”) approved an amendment (the “Amendment”) to that certain employment letter, dated January 5, 2015, as subsequently amended on January 16, 2015, July 25, 2016 and September 18, 2017, by and between the Company and David J. Mazzo, Ph.D., the Company’s President and Chief Executive Officer (as subsequently amended, the “Employment Agreement”).
The Amendment provides for the inclusion of a modified economic cutback provision to the severance provision contained in the Employment Agreement.
The foregoing description of the Amendment is not complete and is subject to and qualified in its entirety by reference to the full text of the Amendment, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
|Item 9.01||Financial Statements and Exhibits.|
CALADRIUS BIOSCIENCES, INC. ExhibitEX-10.1 2 tv508609_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”),…To view the full exhibit click
About CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS)
Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases.